Last week, Green Thumb Industries (GTBIF Quick QuoteGTBIF - Free Report) reported mixed third-quarter 2026 results. Although earnings missed consensus estimates, sales topped expectations.

The U.S.-based cannabis company reported a loss of 2 cents per share, down from the 10-cent profit posted in the year-ago quarter. Sales rose 11.3% year over year to $324.4 million.

The results highlight Green Thumb's ability to sustain revenue growth despite persistent pricing pressure across the cannabis space. Investors should assess whether the company's regulatory catalysts, financial strength and growth prospects are enough to offset the industry headwinds before making an investment decision.

GTBIF Continues to Grow Despite Industry Headwinds

Green Thumb continues to expand its business despite persistent pricing pressure and increased competition across several cannabis markets. In the first nine months of 2026, revenues increased roughly 8% year over year to $931.3 million. The upside was supported by Minnesota's adult-use market, which began operations in September 2025, as well as continued contributions from established markets, including Florida, New Jersey, New York, Ohio and Virginia. The company also benefited from the recently opened and acquired retail locations.

The company's retail and consumer packaged goods businesses both gained momentum in the third quarter. Retail revenues increased 10% year over year, while comparable-store sales rose 3% across 108 stores, returning to growth for the first time since the third quarter of 2024. This marked an improvement from the approximately 1% decline recorded in the previous quarter. Meanwhile, revenues from consumer packaged goods (CPG) rose 16%, reflecting strength in Minnesota and several of Green Thumb's existing markets. However, management noted that rising competition and price compression continued to weigh on sales in select markets. In Minnesota, the entry of additional dispensaries is also increasing retail competition, although the company sees growing wholesale opportunities as the market develops.

Green Thumb's ability to maintain profitability amid these challenges remains an important part of its investment case. Both the reported gross and EBITDA margins declined year over year in Q3, primarily due to a payment of $15.8 million in brand licensing fees to Rythm. While gross margins fell 420 basis points (bps) to 45.2%, EBITDA margins declined 460 bps to 18.3%.

To support future growth, Green Thumb is continuing to expand its retail footprint and invest in markets with attractive long-term potential. After opening six RISE dispensaries during the third quarter of 2026, the company added three more Florida locations after quarter-end, bringing its Florida portfolio to 27 stores and its national footprint to more than 130 locations. Virginia also represents a significant opportunity, with adult-use sales scheduled to begin in July 2027. Green Thumb already operates six dispensaries and two cultivation facilities in the state, while management believes supply constraints could persist during the initial years of the market's development. The company is also advancing its entry into Texas under a conditional medical cannabis license, although the timing of further investment remains dependent on regulatory developments.

Despite these growth opportunities, management remains cautious about the near-term outlook. Green Thumb expects fourth-quarter revenues to be flat to slightly lower sequentially as pricing pressure persists, although some markets are showing signs of stabilization. The company expects further price compression in the coming quarters, making it important for investors to monitor whether growth in newer markets, improving comparable sales and operating efficiencies can offset the pressure on pricing and margins.

Additionally, Green Thumb began consolidating Rythm, Inc. into its financial statements effective Oct. 10, 2026, following changes to the terms of certain convertible notes and warrants. As a result, Q4 results will not be directly comparable with prior periods, making it harder to assess underlying growth trends.

Green Thumb Returns Capital Amid Uplisting Uncertainty

Green Thumb continues to return capital to its shareholders through its share repurchase program, reflecting management's focus on capital discipline and long-term shareholder value. Since late 2023, the company has repurchased approximately 29.5 million shares for more than $200 million, including over $80 million during 2026. In September, its board authorized an additional $50 million for repurchases through September 2027.

The company ended September with $316 million in cash against $277.3 million in total debt, while generating $58.3 million in operating cash flow during the quarter. This financial flexibility supports its ability to pursue growth investments alongside shareholder returns.

Meanwhile, a potential U.S. exchange uplisting remains a longer-term possibility, although management does not view it as an immediate catalyst. CEO Ben Kovler indicated that a listing alone may not meaningfully improve the company's valuation without greater clarity on federal cannabis scheduling and taxation. Management is also not considering separating its medical business to facilitate an uplisting, citing operational and accounting complexities.

Competitive Landscape

Green Thumb operates in a highly competitive U.S. cannabis market, where established multi-state operators compete for market share through retail expansion, product differentiation and pricing.

Curaleaf Holdings (CURLF Quick QuoteCURLF - Free Report) is one of its key competitors, with a sizeable U.S. retail and wholesale presence. Its expanding retail footprint and broad distribution network make it a formidable competitor for Green Thumb, particularly in overlapping U.S. markets. CURLF is also diversifying its operations by expanding internationally.

Tilray Brands (TLRY Quick QuoteTLRY - Free Report) is another important industry participant, although its business is more diversified than Green Thumb's. In addition to cannabis, Tilray has significant beverage and distribution operations, alongside its wellness business. This broader business mix provides exposure to markets beyond U.S. cannabis, whereas Green Thumb remains more directly tied to the performance and regulatory environment of the U.S. cannabis industry.

GTBIF Stock Performance and Estimates

Shares of Green Thumb have underperformed the industry year to date, as shown in the chart below.

Image Source: Zacks Investment Research

Movements in EPS estimates for 2026 and 2027 have been mixed over the past 7 days.

Image Source: Zacks Investment Research

How to Play GTBIF Stock Now?

Green Thumb's operating performance remains encouraging, but the cannabis industry warrants a cautious approach. The company continues to support shareholder returns through buybacks and has growth opportunities in markets such as Virginia and Florida. However, these positives may take time to translate into stronger earnings growth, particularly as management expects pricing pressure to persist in the coming quarters.

Analyst estimate revisions also offer limited near-term conviction, with 2026 estimates moving lower and 2027 estimates edging up only slightly. Given the industry's structural challenges and the absence of clear evidence of a sustained recovery in pricing and margins, investors may prefer to wait for greater visibility on Green Thumb's earnings trajectory before taking a fresh position. GTBIF stock carries a Zacks Rank #3 (Hold), supporting a wait-and-watch approach.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.